Results 1 to 10 of about 3,290,621 (312)
Most breast cancer patients are estrogen receptor positive and thus benefit from treatments that inhibit estrogen production; however, one third of tamoxifen-treated patients develops resistance and relapse. Here the authors show that tamoxifen resistant
Yinghua Zhu +17 more
doaj +1 more source
Background All-trans retinoic acid (ATRA) is an indispensable part of the treatment of acute promyelocytic leukemia (APL). Although, mild cutaneous toxicities like mucocutaneous xerosis, rash, and pruritus are well reported, ATRA associated severe ...
Aisha Jamal +5 more
doaj +1 more source
P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML
L. E. Aguirre +9 more
doaj +1 more source
LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
Cyclin D1 is involved in tamoxifen resistance in breast cancer (BC) but how it is regulated is unclear. Here, the authors demonstrate that the LncRNA DILA1 contributes to tamoxifen resistance in breast cancer by binding to Cyclin D1 and preventing its ...
Qianfeng Shi +14 more
doaj +1 more source
Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small-cell lung cancer. Duo to the current lack of precise targeted therapies, there is an urgent need to identify novel therapeutic targets.
Binghua Tan +14 more
doaj +1 more source
Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms
The benefits of lenalidomide, which leverages TP53-dependent apoptosis and promotion of megakaryocytic differentiation, in lower-risk MDS (LR-MDS) with del(5q) are well-established and drive its frequent use in clinical practice. In parallel, advances in
Bahga Katamesh, Rory M. Shallis
doaj +1 more source
MECOM-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies
Acute myeloid leukemia (AML) is an aggressive clonal hematopoietic malignancy, characterized by marked biological heterogeneity and variable clinical outcomes. Among its rarer genetic subsets is AML with rearrangements of the MDS1 and EVI1 complex locus (
Utsav Joshi, Rory M. Shallis
doaj +1 more source

